← FDA DRUG APPROVALS
FDA ANDA · ANDA083573
HYDROCHLOROTHIAZIDE W/ RESERPINE
Sponsor: IVAX SUB TEVA PHARMS
APPLICATION
ANDA083573
TYPE
ANDA
ORIGINAL APPROVAL
1973-12-11
LATEST ACTION
1997-09-09
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
HYDROCHLOROTHIAZIDE W/ RESERPINEDiscontinued
HYDROCHLOROTHIAZIDE 50MG, RESERPINE 0.125MG · TABLET · ORAL
Approval history
1997-09-09Labeling · Supplement 68AP
1973-12-11OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.